

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 109993		APPLICATION NO. New U.S. Patent Application	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S)			
				FILING DATE December 21, 2001			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
	1	5,126,433	06/30/1992	Maddon et al.			
	2	5,871,913	02/16/1999	Maddon et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
	3	WO 94/19017	09/01/1994	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	4	Kamel Sanhadji et al., "Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice", AIDS, pp2813-2822, Vol. 14, No. 18, 2000					
	5	Sarah S. Frankel et al., "Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells", Journal of Virology, pp. 9788-9794, Vol. 72, No. 12, 1998					
	6	Sophie Ugolini et al., "Inhibition of Virus Attachment to CD4 ⁺ Target Cells Is a Major Mechanism of T Cell Line-adapted HIV-1 Neutralization", J. Exp. Med., pp.1287-1298, Vol. 186, No. 8, 1997					
	7	Nancy Sullivan et al., "CD4-Inducted Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization", Journal of Virology, pp.4694-4703, Vol. 72, No. 6, 1998					
	8	Anthony J. Conley et al., "The Consequence of Passive Administration of an Anti-Human Immunodeficiency Virus Type 1 Neutralizing Monoclonal Antibody before Challenge of Chimpanzees with a Primary Virus Isolate", Journal of Virology, pp. 6751-6758, Vol. 70, No. 10, 1996					
	9	Anthony J. Conley et al., "Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody", Proc. Natl. Acad. Sci., pp. 3348-3352, Vol. 91, 1994					
	10	Alexandra Trkola et al., "Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents is Independent of Coreceptor Usage", Journal of Virology, pp. 1876-1885, Vol. 72, No. 3, 1998					
	11	P. J. Klasse et al., "Quantitative Model of Antibody- and Soluble CD4-Mediated Neutralization of Primary Isolates and T-Cell Line-Adapted Strains of Human Immunodeficiency Virus Type 1", Journal of Virology, pp. 3668-3677, Vol. 70, No. 6, 1996					
	12	Dominik Schenten et al., "Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells", Journal of Virology, pp. 5373-5380, Vol. 73, No. 7, 1999					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Application No.: New U.S. Patent Application

Filed: December 21, 2001

Docket No.: 109993

For: GENE THERAPY USING ANTI-GP41 ANTIBODY AND CD4 IMMUNOADHESIN



INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. Relevance of the English language reference 3 is discussed in the present specification.

Respectfully submitted,

William P. Berridge
Registration No. 30,024

Melanie L. Mealy
Registration No. 40,085

WPB:MLM/mlb
Date: December 21, 2001

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

